Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
Total equity and debt raising of ~$90 million provides runway to 2H 2027
Strong support from existing and new investors including SPRIM Global Investments
Funds will be used to scale-up production of needle-free vaccination delivery technology
Founding CEO David Hoey will transition to Strategic Advisor
Company well-advanced in search for new CEO to accelerate commercialisation.
BRISBANE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd, the biotechnology company pioneering the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, today announced that it has secured ~$90 million in its latest financing round.
The financing is one of the largest financings for a private biotech company in Australia this year and includes $49.22 million in new Series D equity and $40 million in debt facilities, with additional commitments under discussion as the Company continues to attract investor interest.
The equity financing was led by SPRIM Global Investments, the venture arm of global life sciences firm SPRIM, with strong participation from new investor LGT Crestone as well as existing investors OneVentures and Brandon Capital-Hostplus.
The funding will enable Vaxxas to accelerate the development and scale-up of its HD-MAP technology towards market readiness, including installation of semi-automated manufacturing lines and later-stage clinical trial programs.
Vaxxas' HD-MAP technology represents a major advance in vaccine delivery, enabling needle-free administration that reduces temperature control requirements for vaccine storage and creates opportunities for self-administration in the home. This could dramatically improve vaccine access and uptake worldwide.
Chair of Vaxxas, Sarah Meibusch, said the capital raising represented an excellent achievement in a very difficult market for biotech. "This result underscores the confidence that leading investors have in Vaxxas' disruptive technology and the progress the team has made toward scaling-up and commercialisation. Coupled with our sharp focus on commercialisation, this funding provides Vaxxas with a runway into the second half of 2027 as we focus on bringing our technology to market."
Michael Shleifer, Co-Founder and Managing Partner of SPRIM Global Investments, said: "SPRIM is proud to lead this financing and support Vaxxas at this exciting juncture. We believe the HD-MAP platform has the potential to fundamentally transform vaccine delivery globally, expanding access, reducing costs, and improving uptake. The commercial opportunity is enormous, and we look forward to partnering ...
